Supplementary figure and table
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background/Aim: Oncological outcomes for metastatic castration-sensitive prostate cancer (mCSPC) have improved with upfront androgen receptor signaling inhibitor (ARSI) doublet therapy. However, the prognostic value of prostate-specific antigen (PSA) kinetics in real-world settings remains unclear. This study aimed to evaluate the clinical significance of PSA kinetics in high-risk mCSPC patients. Patients and Methods: We retrospectively analyzed 352 patients with de novo high-risk mCSPC from the ULTRA-J database who received upfront ARSI doublet therapy between 2014 and 2023. PSA kinetics, including PSA nadir, PSA response rate, and time to PSA nadir (TTN), were assessed. Associations with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models. Results: A PSA nadir ≤0.02 ng/mL and PSA response rate ≥99% were significantly associated with prolonged CRPC-FS and OS (p < 0.05). Conversely, TTN ≤3 months was associated with poorer outcomes. Multivariate analysis identified PSA nadir >0.02 ng/mL, PSA response rate
Fields of Study & Subjects
Prostate Cancer Treatment and Research
Prostate Cancer Diagnosis and Treatment
Bone health and treatments
Publication details
- Journal / source
- Figshare
- Publication date
- 28 March 2026
- Language
- EN